Larimar Therapeutics (LRMR) Stock Forecast: StockMap's 2-Week Call
LRMR stock forecast: StockMap's model makes no two-week call on Larimar Therapeutics after the Nov 13 close: its evidence is split, 5 reasons for and 10 against. Right in 2 of 3 two-week windows on LRMR since Sep 24; by chance, a call on the same dates was right 51% of the time.
Larimar Therapeutics last closed at $3.02, +11.85% on the session.
Against the IVW growth benchmark the position is +12.76% over the forecast window.
Larimar Therapeutics' market cap is $313.72M as of November 13, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -13 (too close to call).
Where LRMR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 67%.
22 daily calls for LRMR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Larimar Therapeutics in the 8th percentile on return on equity, where 100 is best.
Larimar Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Larimar Therapeutics as the 204th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite Larimar Therapeutics ranks 133rd of 391 in the group, against a group median of -0.24.